Related Experiment Video

Updated: May 12, 2026

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
08:26

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer

Published on: March 24, 2013

Eribulin for advanced breast cancer: a drug evaluation

Alaaeldin Shablak1

  • 1Department of Medical Oncology, Bradford Royal Infirmary, Bradford, UK.

Journal of Breast Cancer
|April 18, 2013
PubMed

Insights

Eribulin, a synthetic microtubule inhibitor, shows promise in treating advanced breast cancer by improving patient survival. This review details its pharmacology, clinical efficacy, and safety in oncology.

Area of Science:

  • Oncology
  • Pharmacology
  • Marine Natural Products

Background:

  • Eribulin is a synthetic analog derived from halichondrin B, a marine natural product.
  • It functions as a microtubule dynamics inhibitor.
  • Demonstrated activity against various malignancies in preclinical studies.

Purpose of the Study:

  • To provide a comprehensive overview of eribulin's therapeutic application in oncology.
  • To review its pharmacology, pharmacokinetics, clinical efficacy, and safety profile.
  • To discuss potential economic factors associated with eribulin treatment.

Main Methods:

  • Review of advanced phase clinical trials.
  • Analysis of preclinical in vitro and in vivo data.
  • Synthesis of information on pharmacology and pharmacokinetics.

Main Results:

  • Eribulin demonstrated efficacy in pretreated advanced breast cancer patients.
  • Improved survival rates were observed in clinical trials.
  • Favorable safety profile noted in patient populations.

Conclusions:

  • Eribulin is a valuable therapeutic option for advanced malignancies, particularly breast cancer.
  • Its unique mechanism of action and clinical benefits support its role in oncology.
  • Further evaluation of economic impact is warranted.
Keywords:
Breast neoplasmsEribulinMicrotubule inhibitor

More Related Videos

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...